Project description:Experiments to test the effect of CtBP2 inhibition on metabolism of breast cell lines. In particular, experiment 1 involves comparison between a normal breast cell line (MCF102A) and a triple-negative breast cancer cell line (MDA-MB231). Experiment 2 is a study between MDA-MB231 silenced for CtBP2 by stable RNA interference (shCtBP2 cells) compared to scramble (shCTRL cells). Experiment 3 is a comparison between a normal breast cell line (MCF102A) and a triple-negative breast cancer cell line (MDA-MB231)in the presence of the absence of small-molecule CtBP inhibitors: HIPP (400 μM) or P4 (300 μM)for 48 hours.
Project description:RNA-sequencing data from MDA-MB231 breast cancer cells, U87MG glioblastoma cells, and mouse breast cancer PDX models treated with antisense oligonucleotides targeting exon 2 of TRA2B. Additionally, RNA-sequencing data from MDA-MB231 breast cancer cells and U87MG glioblastoma cells treated with siRNAs targeting TRA2B. RNA-sequencing data from MDA-MB231 breast cancer cells nad U87MG glioblastoma cells treated with antisense oligonucleotides targeting exon 2 of TRA2B.
Project description:Here, we performed N-glycoproteomics on six triple negative breast cancer cell lines (commercially available cell lines: HCC1187, HCC1937, MDA-MB157, MDA-MB231, MDA-MB436, MDA-MB468) and five normal control cell lines (commercially available MCF10A and 4 non-immortalized human mammary epithelial cells: HMEC_RM10, HMEC_RM1, HMEC_RM2, HMEC_HB5) using hydrazide-based enrichment. Quantitative proteomics and integrative data mining led to the discovery of Plexin B3 (PLXNB3) as a previously undescribed TNBC-enriched cell surface protein.
